Biomark Diagnostics Inc. (FRA:20B)
Germany flag Germany · Delayed Price · Currency is EUR
0.3540
-0.0040 (-1.12%)
At close: Mar 20, 2026

Biomark Diagnostics Balance Sheet

Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Cash & Equivalents
0.492.480.160.070.380.88
Cash & Short-Term Investments
1.292.480.160.070.380.88
Cash Growth
1351.96%1483.27%117.59%-81.18%-56.39%43.46%
Accounts Receivable
0.190.160.040.030.08-
Other Receivables
-----0.03
Receivables
0.190.160.040.030.080.03
Prepaid Expenses
---0.020.030.02
Total Current Assets
1.482.640.20.130.50.92
Property, Plant & Equipment
0.60.450.850.590.970.03
Long-Term Investments
000000
Other Long-Term Assets
0.050.030.030.01--
Total Assets
2.143.131.090.731.470.95
Accounts Payable
0.220.270.140.220.130.03
Short-Term Debt
-0.660.741.061.060.89
Current Portion of Long-Term Debt
---0.1--
Current Portion of Leases
0.320.290.350.280.30.01
Other Current Liabilities
0.690.010.010.010.01-
Total Current Liabilities
1.231.231.241.661.50.92
Long-Term Debt
----0.10.09
Long-Term Leases
0.390.160.450.220.510.02
Total Liabilities
1.631.391.71.882.111.03
Common Stock
13.7813.7810.148.247.126.88
Additional Paid-In Capital
3.783.732.352.231.71.63
Retained Earnings
-17.05-15.77-13.45-11.98-10.12-8.59
Comprehensive Income & Other
--0.350.360.660
Shareholders' Equity
0.511.74-0.61-1.15-0.64-0.08
Total Liabilities & Equity
2.143.131.090.731.470.95
Total Debt
0.711.121.551.651.971
Net Cash (Debt)
0.571.36-1.39-1.58-1.58-0.13
Net Cash Per Share
0.010.01-0.02-0.02-0.02-0.00
Filing Date Shares Outstanding
105.09105.0990.8983.2977.9777.97
Total Common Shares Outstanding
105.09105.0990.8983.2977.9776.78
Working Capital
0.241.41-1.04-1.54-10
Book Value Per Share
0.000.02-0.01-0.01-0.01-0.00
Tangible Book Value
0.511.74-0.61-1.15-0.64-0.08
Tangible Book Value Per Share
0.000.02-0.01-0.01-0.01-0.00
Machinery
0.080.070.070.060.06-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.